Dyne Therapeutics (NASDAQ:DYN) Reaches New 1-Year Low – Here’s Why

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares hit a new 52-week low on Tuesday . The stock traded as low as $9.96 and last traded at $10.46, with a volume of 2930532 shares. The stock had previously closed at $11.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Scotiabank started coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. Piper Sandler decreased their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Down 8.6 %

The business’s fifty day moving average price is $13.20 and its 200 day moving average price is $23.23. The firm has a market capitalization of $1.18 billion, a PE ratio of -2.94 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 6,237 shares of company stock valued at $77,760 over the last quarter. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $50,000. Neo Ivy Capital Management purchased a new position in Dyne Therapeutics during the fourth quarter worth approximately $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Dyne Therapeutics by 6.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after purchasing an additional 9,029 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $2,804,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Dyne Therapeutics by 25.4% during the 4th quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock worth $1,793,000 after buying an additional 15,400 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.